MedTrace Logo

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV

NCT00516685 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2011-09-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).

Conditions

  • Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV

Interventions

BIOLOGICAL

Recombinant Human rEGF-P64K/Montanide Vaccine

Sponsors & Collaborators

  • Bioven Sdn. Bhd.

    lead INDUSTRY

Principal Investigators

  • G SELVARATNAM, MD · NILAI CANCER INSTITUTE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516685 on ClinicalTrials.gov